Roche's bid to expand HPV test could edge out Pap

Share this article:

Roche Diagnostics originally scored an approval to market its Cobas HPV diagnostic for use along with the older cervical-cancer Pap test, but a request it just filed with the FDA could give the drug maker a primary screening indication. If approval is granted, Roche said, Cobas could become the first-line diagnostic for use in screening women for cervical cancer, rather than the Pap smear currently used as part of a greater screening strategy for the disease.

Cobas is the only diagnostic that provides pooled results for high-risk genotypes, including individual results for the two highest-risk genotypes, HPV 16 and HPV 18—a point of differentiation from Qiagen's Digene test and Hologic's Cervista assays.

The test was approved in April 2011 to screen adults over 21 years of age with abnormal Pap test results and to co-test with Pap in older women to assess the presence or absence of high-risk HPV genotypes. It received the CE mark in the EU last November.

In a statement issued yesterday, Roche said research shows that incorporating high-risk HPV DNA testing with simultaneous detection of genotypes 16 and 18 as an initial screening test can detect more cervical disease than strategies that use Pap alone.

The National Cancer Institute estimates there are 12,200 new cases of cervical cancer in the US each year and 4,200 will die from the disease in the same time frame.

In related news, researchers found that too few doctors are following guidelines for cervical cancer and HPV screening, Healthday News reports today. In the survey of 366 US-based obstetricians-gynecologists, less than one-third said they vaccinate eligible patients against HPV. Only half follow cervical cancer prevention guidelines.

HPV screening is recommended for females ages 11-26, although current guidelines issued by the American Congress of Obstetricians and Gynecologists suggest women aged 21-29 receive a Pap smear once every two years and, from 30 on, once every three years if they've had either prior normal Pap test results or negative results on tests for HPV.

When asked by the researchers what was keeping them from vaccinating eligible patients, most doctors cited parent and patient refusals.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...